LL-37 is the sole human cathelicidin antimicrobial peptide, a 37-amino-acid molecule that serves as a critical component of the innate immune system. Beyond its direct antimicrobial properties, LL-37 functions as an immunomodulator, wound healing promoter, and regulator of inflammatory responses. Research into LL-37 spans infectious disease, wound healing, cancer biology, and autoimmune conditions, making it one of the most versatile host defense peptides studied.
Structure and Expression
LL-37 is derived from the 18 kDa precursor protein hCAP-18 (human cationic antimicrobial protein of 18 kDa), which is cleaved by proteinase 3 to release the active C-terminal peptide. The mature peptide contains a net positive charge (+6 at physiological pH) and adopts an amphipathic alpha-helical conformation in membrane environments—a structure critical for both its antimicrobial and immunomodulatory activities.
Expression of hCAP-18/LL-37 occurs in neutrophils (stored in specific granules), macrophages, monocytes, mast cells, epithelial cells of the skin, respiratory tract, gastrointestinal tract, and urogenital tract. Expression is upregulated by vitamin D3 signaling through the vitamin D receptor (VDR), which binds directly to vitamin D response elements in the cathelicidin gene promoter. This vitamin D-LL-37 axis has important implications for immune function research.
Antimicrobial Mechanisms
LL-37’s primary antimicrobial mechanism involves disruption of microbial membranes. The peptide’s cationic residues are attracted to negatively charged bacterial membranes (rich in phosphatidylglycerol and lipopolysaccharide) while showing less affinity for neutral mammalian membranes (rich in phosphatidylcholine and cholesterol). Upon binding, LL-37 adopts its alpha-helical structure and integrates into the lipid bilayer.
Several models describe the membrane disruption process. The toroidal pore model suggests LL-37 monomers form transmembrane pores lined by both peptide and lipid molecules. The carpet model proposes that peptides accumulate on the membrane surface until a critical concentration causes detergent-like membrane dissolution. In practice, LL-37 likely employs both mechanisms depending on peptide concentration and membrane composition.
LL-37 also demonstrates potent anti-biofilm activity. Biofilms—structured bacterial communities encased in protective extracellular matrix—are notoriously resistant to conventional antibiotics. LL-37 disrupts biofilm formation at sub-inhibitory concentrations by interfering with quorum sensing, reducing bacterial surface attachment, and degrading established biofilm matrix. This anti-biofilm activity has been demonstrated against Pseudomonas aeruginosa, Staphylococcus aureus, and other clinically relevant species.
Immunomodulatory Functions
Beyond direct microbial killing, LL-37 serves as a signaling molecule that bridges innate and adaptive immunity. The peptide is chemotactic for neutrophils, monocytes, T cells, and mast cells through formyl peptide receptor-like 1 (FPRL1) activation. This recruitment of immune cells to infection sites amplifies the host defense response.
LL-37 modulates cytokine and chemokine production in complex, context-dependent ways. It can suppress LPS-induced TNF-alpha and IL-6 production (anti-inflammatory effect) while simultaneously promoting IL-8 and MCP-1 release (pro-inflammatory effect). This dual modulation allows LL-37 to promote pathogen clearance while limiting excessive inflammatory tissue damage. The peptide also enhances macrophage phagocytosis and promotes neutrophil extracellular trap (NET) formation.
Wound Healing Research
LL-37 promotes wound healing through multiple mechanisms. It stimulates keratinocyte migration via EGFR transactivation, promotes angiogenesis through VEGF-independent pathways involving FPRL1 signaling, and enhances fibroblast proliferation and collagen production. In wound models, LL-37 application accelerated re-epithelialization and granulation tissue formation.
The peptide’s wound healing effects are particularly relevant because LL-37 expression is naturally upregulated at wound sites. Patients with chronic non-healing wounds often show reduced LL-37 levels at the wound bed, suggesting a connection between cathelicidin deficiency and impaired healing.
Antiviral Research
LL-37 demonstrates activity against several enveloped viruses including influenza A, respiratory syncytial virus (RSV), herpes simplex virus, and HIV. The primary mechanism involves disruption of the viral envelope, analogous to bacterial membrane disruption. LL-37 also inhibits viral attachment and entry by binding to cell surface receptors used by viruses, and it can stimulate antiviral immune responses through interferon pathway activation.
Research Challenges
LL-37 research faces several practical challenges. The peptide is relatively large (37 amino acids) and expensive to synthesize. Its amphipathic nature can cause aggregation in aqueous solution and non-specific binding to experimental materials. LL-37 is also susceptible to proteolytic degradation in biological fluids, limiting its half-life in vivo. Researchers have developed various truncated analogs and chemical modifications to address these limitations while retaining biological activity.
Frequently Asked Questions
What is LL-37?
LL-37 is a 37-amino-acid antimicrobial peptide and the only human cathelicidin. It is produced by immune cells, epithelial cells, and keratinocytes and plays essential roles in innate immunity, wound healing, and inflammatory regulation.
How does LL-37 kill bacteria?
LL-37 disrupts bacterial membranes through electrostatic interaction between its cationic residues and the negatively charged bacterial membrane phospholipids. It adopts an alpha-helical structure that inserts into lipid bilayers, forming pores or carpeting the surface, leading to membrane depolarization and cell death.
Does LL-37 only fight bacteria?
No. LL-37 has activity against bacteria, fungi, viruses (including enveloped viruses), and biofilms. Beyond direct antimicrobial action, it also functions as an immunomodulator, chemoattractant for immune cells, wound healing promoter, and angiogenesis stimulator.